The article presents current data on the prevalence and etiology of community-acquired pneumonia, shows the contribution of each of the possible pathogens to the structure of the disease. The diagnostic criteria for pneumonia are given. The main algorithms for assessing the severity of pneumonia and the prognosis of the disease using different scales: CURB-65 / CRB-65, PORT (PSI), are described. The purpose of the test is to determine the place of treatment: outpatient or in the in-patient department, in the general department or in the intensive care unit. The criteria for IDSA / ATS (American Thoracic Society / American Society of Infectious Diseases), as well as the SMART-COP / SMRCO scale to determine the need for hospitalized patients in the intensive care unit, are reviewed. The Aliberti and PES scales are given, assessing the risk of the presence of resistant pathogens in community-acquired pneumonia. Modern recommendations on the empirical choice of antibacterial drugs depending on individual patient factors are presented: anamnestic indications for treatment with antimicrobials during the preceding three months, hospitalization within six months before the onset of pneumonia, the presence of comorbidities, the severity of the disease, the risk of resistant pathogens. The average therapeutic doses of antibacterial drugs for the treatment of community-acquired pneumonia in patients with normal renal function are indicated. The questions of the optimal duration of treatment of pneumonia depending on the etiology are considered, the criteria of sufficiency of antibacterial therapy are presented. The reasons for the possible ineffectiveness of the empirical antibiotic therapy of community-acquired pneumonia are described. The importance of identifying a particular form of community-acquired pneumonia – severe community-acquired pneumonia is emphasized. Described drugs for the treatment of severe community-acquired pneumonia. The issues of prevention of pneumonia were discussed, its importance in the strategy of reducing mortality according to the World Health Organization was emphasized.
15 August 2026 in Pharmacogenetics and Pharmacogenomics
Objective. To systematically review and critically appraise current evidence on genetic markers associated with the efficacy of anti-VEGF therapy in neovascular age-related macular degeneration (nvAMD). Methods. A literature analysis covering the period 2005–2025 was performed, including candidate gene studies, meta-analyses, and genome-wide association studies (GWAS). Genetic variants in CFH, ARMS2/HTRA1, VEGFA, KDR, IL8, and SIRT1 genes were examined. Results. The most reproducible associations with anti-VEGF response were found for CFH rs1061170 (Y402H), ARMS2 rs10490924, IL8 rs4073 (-251A/T) и VEGFA rs699947 polymorphisms. According to meta-analyses, carriage of the CFH rs1061170 risk allele is associated with reduced functional response (pooled OR=1.34, 95 % CI 1.10–1.63). However, the effect size is modest, results differ between European and Asian populations, and large RCTs have not confirmed the clinical utility of single SNPs. None of the studied markers possess sufficient predictive value for standalone use in routine practice. Conclusion. Genetic markers associated with anti-VEGF therapy efficacy in nvAMD show moderate and heterogeneous effects. The development of polygenic prognostic models combining multiple SNPs with clinical and imaging parameters is a promising direction.
25 August 2026 in Safety and Risk of Pharmacotherapy
INTRODUCTION. Combined psychopharmacotherapy in patients with comorbid psychiatric and somatic disorders creates a high risk of adverse drug reactions (ADRs). The Global Trigger Tool (GTT) enables active screening and quantitative assessment of ADRs developing under the influence of various factors in routine clinical practice and helps identify directions for optimizing therapeutic strategy. AIM. To evaluate the frequency and structure of ADRs during psychopharmacotherapy in patients with a psychosomatic profile and to identify associations between the use of specific drugs, combined psychopharmacotherapy, and the development of ADRs using the Global Trigger Tool. MATERIALS AND METHODS. A single-center retrospective study was conducted that included 491 medical records of patients hospitalized in a psychosomatic department from January 2024 to March 2025. A list of 27 triggers, adapted for patients receiving psychopharmacotherapy, was used to identify ADRs. Statistical analysis was performed using Fisher exact test. RESULTS. Twenty-five types of ADRs were identified. The most frequently recorded were cardiovascular disorders ( n =211), anticholinergic effects ( n =113), and hematological reactions ( n =89). Concomitant use of 2 or more psychotropic drugs was associated with an increase in the incidence of extrapyramidal symptoms (up to 14.1%, p <0.001), acute urinary retention (up to 12.7%, p <0.001), and arterial hypotension (up to 9.4%, p <0.001) that correlated with the number of psychotropic drugs used. Known associations were confirmed: antipsychotics with extrapyramidal symptoms; antidepressants with bleeding; and antiepileptics with hematotoxicity. New hypotheses requiring confirmation were generated: risk of thrombocytopenia with trihexyphenidyl (p=0.006) and periciazine ( p =0.005); arterial hypotension with valproic acid ( p =0.044); and cardiotoxicity of pramipexole ( p =0.006) and levodopa ( p =0.012). CONCLUSIONS. The GTT is an effective method for retrospective safety audit of psychopharmacotherapy. Combined psychopharmacotherapy is an independent modifiable risk factor. New associations between specific drugs and ADRs were identified that require confirmation and validation in prospective studies.
Background : the issues of diagnosis and prevalence of infectious complications (ICs) in patients with mental disorders remain insufficiently studied. Diagnosing ICs in this population is challenging due to poor patient cooperation, atypical presentation of infections, and masking of symptoms by the underlying psychiatric illness. Classical markers of infection are often non-specific or lack sensitivity, highlighting the need for more reliable diagnostic and prognostic criteria. The aim of study was to investigate the incidence and clinical-laboratory features of ICs in psychiatric patients to develop specialized algorithms for early diagnosis and treatment. Patients and Methods : a retrospective, non-interventional study was conducted based on the analysis of the “CLIOPS” database. The study included 727 patients (385 men and 342 women; mean age 62 ys), divided into two groups: without IC (n = 360) and with IC (n = 367). Anthropometric, demographic, clinical, and laboratory data were analyzed. Results : the most vulnerable group were patients with organic mental disorders (52.9% of all patients with ICs). The leading ICs were pneumonia (59.7%) and urinary tract infections (13.9%). Patients with IC had significantly more frequently: longer hospitalization, higher Waterlow scale scores, elevated CRP levels (99.2% vs 0.8%), leukocytosis (82.6% vs 55.8%), and changes in psychotic status (9.3% vs 1.7%). Fever was absent in 35.6% of patients with ICs. The strongest predictors of IC were: elevated CRP (OR = 50.2), fever > 38 °C (OR = 40.9), and altered mental status (OR = 6.02). Conclusion : diagnosing IC in patients with mental disorders requires a comprehensive approach due to the frequent absence of classic symptoms. The most significant markers of IC are elevated CRP and sudden decompensation of mental state. The lack of productive communication with the patient is a key factor complicating diagnosis. It is necessary to implement targeted screening algorithms for at-risk groups (patients with organic mental disorders), mandatorily including CRP testing and thorough assessment of mental state for early infection detection and therapy initiation.
Background: Ketoprofen is one of the most commonly prescribed NSAIDs; however, its pharmacogenetics remains poorly understood. The objective was to evaluate the influence of patients’ pharmacogenetic profiles on the effectiveness of ketoprofen for postoperative pain management after total hip arthroplasty, including postoperative analgesia (pain levels, opioid consumption) and the incidence of adverse reactions during hospitalization and up to 12 months post-surgery. Methods: The study included 53 patients (31 (58.49%) women, median age 66.0 [60.0–74.0] years) undergoing total hip arthroplasty. Genotyping was performed using real-time PCR to analyze 18 single-nucleotide polymorphisms (SNPs) across the following genes: CYP2C9 (rs1799853, rs1057910), CYP2C8 (rs10509681, rs11572080), CYP3A4 (rs35599367), CYP3A5 (rs776746), UGT2B7 (rs73823859, rs7439366, rs7668282), ABCB1 (rs1045642, rs4148738, rs2032582, rs1128503), PTGS1 (rs10306135, rs12353214), PTGS2 (rs20417), C3orf20 (rs12496846), and ZNF493-ZNF429 (rs2562456). Results: We did not find significant associations between patients’ genotypes and pain levels or postoperative opioid analgesic consumption or adverse reactions when ketoprofen was used for pain management in patients undergoing total hip arthroplasty. Conclusions: Routine pharmacogenetic testing for ketoprofen is not supported by our findings.
Objective. To analyze effectiveness and safety of transcatheter arterial embolization for the treatment of upper gastrointestinal bleeding and compare these results with national and international data. Material and methods. A retrospective analysis of local database included patients with gastroduodenal bleeding for the period from 08.2022 to 12.2024. There were 48 patients including 28 (58.3%) men and 20 (41.6%) women. Mean age of patients was 67.9±11.4 years. Own results were compared with national and international data. Results. There were the following causes of bleeding: various gastric and duodenal tumors — 30 (62.5%); acute and chronic gastric and duodenal ulcers — 16 (33.3%); erosive gastritis, esophagitis — 3 (6.25%). Primary inefficiency of endoscopic hemostasis was noted in 7 patients. In other 41 patients, endoscopic hemostasis was effective. Technical success rate was 100% (48 patients). Recurrence of bleeding was observed in 2 (4%) patients after 2 and 11 days. There was 1 complication (shoulder hematoma without necessary surgical correction). Mean hospital-stay was 15 days. Mortality rate was 33.3% (n=16); 32 (66.7%) patients were discharged. Conclusion. Transcatheter arterial embolization is a quick, safe and effective minimally invasive alternative to surgery, when endoscopic treatment does not allow upper gastrointestinal bleeding control. The advantages of arterial embolization are feasibility of this method in high risk patients, combination of diagnostic angiography to identify the cause of bleeding, rapid hemostasis compared to other instrumental methods.